人工智能驱动的非专利制药化合物的分子生成,使用世界开放专利数据
Yugo Shimizu1,2, Masateru Ohta1, Shoichi Ishida3
1HPC- and AI-driven Drug Development Platform Division, RIKEN Center for Computational Science, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa, 230-0045, Japan.
Journal of cheminformatics
|December 14, 2023
概括
这项研究引入了一种新的AI驱动的方法,通过纳入专利地位来产生药物化合物. 这种方法有效地创造了新的,类似药物的分子,与制药专利景观保持一致.
科学领域:
- 药用化学 医学化学
- 人工智能的人工智能
- 知识产权法 知识产权法 知识产权法
背景情况:
- 开发新型化合物对于新药生产至关重要.
- 对于制药公司来说,确认新化合物的专利地位至关重要.
- 人工智能的进步使大规模的化合物产生成为可能,但由于缺乏可访问的工具和全面的数据库,专利新性评估仍然具有挑战性.
研究的目的:
- 开发一种新的分子生成方法,考虑化合物的专利地位.
- 创建一个可搜索的药物相关专利化合物的参考数据库.
- 为了能够在制药专利约束范围内有效地提出新型化合物.
主要方法:
- 利用SureChEMBL和谷歌专利公开数据库建立与药物相关的专利化合物的参考数据库.
- 使用InChIKey和关系数据库实现了精确结构搜索系统.
- 使用与药物相关的专利化合物作为生成AI的培训数据,将专利地位纳入学习过程.
主要成果:
- 成功构建了一个参考数据库和专利化合物的高效搜索系统.
- 通过专利化合物的数量和它们的状态来指导成功的分子生成.
- 通过将专利信息集成到AI学习中,实现了具有高药物相似性的新型分子的生成.
结论:
- 开发的AI方法通过考虑制药专利信息,有效地产生具有高度药物相似性的新分子.
- 这种方法有助于有效地提出与药物专利相关的新化合物.
- 这项研究为一种新的分子生成策略做出了贡献,该策略整合了专利地位,这是药物发现中以前未被充分利用的特征.
相关概念视频
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Drug Nomenclature
1.8K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.8K
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Structure-Activity Relationships and Drug Design
728
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
728


